Business & Finance
EpiCept reports first quarter loss of $56.6 million following Maxim merger
Published in Clinical Trials Week, June 22nd, 2006
On January 4, 2006, EpiCept completed its merger with Maxim Pharmaceuticals, Inc. The new company combines a relatively lower-risk product pipeline of commercially promising topical pain therapies with the upside potential of a late-stage cancer product and the biopharmaceutical discovery capabilities for apoptosis inducers designed to address unmet medical needs in oncology. On February 7, 2006, EpiCept announced that it raised $11.6 million in gross proceeds through a private placement of common stock and warrants.
"Our path...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2006-06-22)
More Articles from Clinical Trials Week
- Congenital Heart Disease
Hyperventilation is ineffective to reduce arterial-to-end-tidal CO2 tension difference - Diabetes Therapy
Rosiglitazone eased postprandial neutrophils and proinflammatory cytokines rises in diabetes - Diet & Nutrition
Subjects free from peripheral artery disease were associated with higher nutrient intake - Parkinson Disease Therapy
Selegiline slows progression of Parkinson disease symptoms - Acid Reflux
Study shows erosive esophagitis healing linked to gastric acid control - Alzheimer Disease
Alzheimer disease etiology can be influenced by the mitochondrial genome - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
